Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alexion Pharmaceuticals Inc announces European Commission grants orphan drug designation to Soliris (Eculizumab) for prevention of Delayed Graft Function after Solid Organ Transplantation


Monday, 24 Feb 2014 06:30am EST 

Alexion Pharmaceuticals Inc:European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function (DGF) after solid organ transplantation.DGF is an early and serious complication of organ transplantation that is characterized by the failure of a transplanted organ to function normally immediately following transplantation.Says in patients undergoing kidney transplantation, patients who develop DGF require dialysis in order to survive.Grants orphan medicinal product status to provide incentives to develop medicinal products to treat, prevent or diagnose diseases or conditions that affect no more than five in 10,000 persons in the EU. 

Company Quote

194.15
3.13 +1.64%
24 Nov 2014